Primary cutaneous BÂ cell lymphomas (CBCL) are chronic diseases with frequent relapses.
Time to next treatment (TTNT) is an endpoint reflecting clinical benefit of treatments including patient perspectives.
The objectives were to evaluate clinical characteristics, survival, prognosis and TTNT in CBCL.
